2019
Providers Increased the Use of Direct Oral Anticoagulants in Patients with Cancer-Associated Thromboembolism without Gaining Complete Confidence: A Health System-Wide Retrospective Registry Study and a Providers' Survey
Pine A, Lee A. Providers Increased the Use of Direct Oral Anticoagulants in Patients with Cancer-Associated Thromboembolism without Gaining Complete Confidence: A Health System-Wide Retrospective Registry Study and a Providers' Survey. Blood 2019, 134: 2097. DOI: 10.1182/blood-2019-130200.Peer-Reviewed Original ResearchCancer-associated venous thromboembolismDirect oral anticoagulantsUse of DOACsLow molecular weight heparinProvider comfort levelMajority of providersHealth systemWarfarin useOral anticoagulantsClinical trialsUtilization of DOACsYale New Haven Health SystemNational Comprehensive Cancer NetworkDifferent anticoagulantsProspective real-world dataCancer-Associated ThromboembolismUse of apixabanUse of enoxaparinUse of rivaroxabanComprehensive Cancer NetworkRetrospective registry studyCancer care centerMolecular weight heparinMore providersClinical trial results
2018
Impact of a Pharmacist Driven Anti-Xa Level Monitoring Protocol on Therapeutic Drug Monitoring Practice Patterns
Effendi M, Stutsky M, Curran C, Owusu K, Lee A. Impact of a Pharmacist Driven Anti-Xa Level Monitoring Protocol on Therapeutic Drug Monitoring Practice Patterns. Blood 2018, 132: 2284. DOI: 10.1182/blood-2018-99-119379.Peer-Reviewed Original ResearchLow molecular weight heparinAnti-Xa levelsAnti-Xa level monitoringRetrospective chart reviewNon-therapeutic levelsEnoxaparin doseAdult patientsChart reviewCommon indicationDose adjustmentNursing staffBody weightDrug monitoringTherapeutic monitoringAbnormal levelsStudy periodExtreme body weightRoutine laboratory monitoringRenal replacement therapyCertain patient populationsMolecular weight heparinFavorable pharmacokinetic profileRisk of toxicityClinical decision makingEnoxaparin therapy